Prognosis value of serum soluble ST2 level in acute ischemic stroke and STEMI patients in the era of mechanical reperfusion therapy

Mechtouff, Laura; Paccalet, Alexandre; Silva, Claire Crola Da; Buisson, Marielle; Mewton, Nathan; Amaz, Camille; Bonnefoy‐Cudraz, Eric; Leboube, Simon; Cho, Tae‐Hee; Nighoghossian, Norbert; Ovize, Michel; Bochaton, Thomas

doi:10.1007/s00415-021-10865-3

Cited by 12 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Experimental studies have indicated the role of neuroinflammatory markers in the disruption of the BBB [2, 17, 18]. Elevated levels of sST2 have been previously reported as a prognostic indicator of AIS in a few studies [3, 4, 6]. One study showed the highest tertile of sST2 levels above a cut-off level of 22.96 ng/mL, which was measured at a median time of 19 h from the onset, and predicted poor outcome and all-cause mortality at 90 days [3].…”

Section: Discussionmentioning

confidence: 99%

“…These baseline measurements were in line with our findings; however, we were not able to report a significant association with the functional outcome in our population. Another recent study that looked into the relationship of sST2 levels in AIS and cardiac patients reported a significant correlation between the levels of sST2 evaluated at 24 h from admission with all-cause mortality at 3 months, but relatively lower levels at baseline and in the subsequent time points were observed in the AIS group [4]. Contrary to these findings, in a multi-marker study conducted by Dieplinger and colleagues, sST2 showed no correlation with functional outcomes [19].…”

Section: Discussionmentioning

confidence: 99%

“…Previous biomarker studies have shown that circulatory proteins expressed during the postischemic mechanism of inflammation and the blood-brain barrier (BBB) disruption [2] may predict outcomes and mortality in 90 days [3][4][5][6][7][8]. However, the clinical utility of biomarkers remains elusive due to the contradictory findings in other studies.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Soluble ST2 Predicts Poor Functional Outcome in Acute Ischemic Stroke Patients

Krishnamoorthy

Singh

Sreedharan

et al. 2023

Cerebrovasc Dis Extra

View full text Add to dashboard Cite

Introduction: There is very limited data on the role of biomarkers correlating with the outcome in acute ischemic stroke (AIS). We evaluated the predictive values of the plasma concentrations of soluble Serum Stimulation-2 (sST2), Matrix Metalloproteinase-9 (MMP-9), and Claudin-5 in AIS. Methods: The biomarker levels in the plasma samples of consecutive AIS patients collected at baseline, 12 hours, and 24 hours from stroke onset, were quantified using immunoassays. Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) and functional outcome at 90 days using the modified Rankin Scale (mRS), with scores of 3-6 defined as poor outcome. Receiver operating characteristic curve analysis and multiple logistic regression was conducted for evaluating the discriminative power of each marker. Results: We included 108 patients in the study (mean age 62.3±11.7 years). Median NIHSS score was 12 [IQR 8-18]. High baseline glucose levels, systolic blood pressure, baseline NIHSS, low ASPECTS (Alberta Stroke Program Early CT Score), and hemorrhagic transformation were associated with poor outcomes. Elevated sST2 at 12 hours (50.4±51.0 ng/mL; P=0.047) and 24 hours (81.8±101.3 ng/mL; P=0.001) positively correlated with poor outcomes. MMP-9 (P=0.086) and Claudin-5 (P=0.2) were not significantly associated with the outcome although increased expressions of both markers were observed at 12 hours. Multiple logistic regression showed that sST2 levels ≥71.8 ng/mL at 24 hours, with a specificity of 96.9%, emerged as an independent predictor of poor functional outcome (OR: 6.44,95% CI:1.40-46.3; P=0.029). Conclusion: Evaluation of soluble ST2 may act as a reliable biomarker of functional outcome in AIS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble ST2 Predicts Poor Functional Outcome in Acute Ischemic Stroke Patients

Krishnamoorthy

Singh

Sreedharan

et al. 2023

Cerebrovasc Dis Extra

View full text Add to dashboard Cite

show abstract

“…The systematic search of online databases yielded 461 non-duplicate records, and 6 articles were acquired by a manual search. After evaluation, 19 articles were included in this systematic review [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] (Fig. 1), of which 10 investigated the value of serum sST-2 measurement in the prediction of the risk of stroke incidence [12][13][14][15][16][17][18][19][20][21], and the remaining 9 evaluated the value of serum sST-2 measurement in the prognosis of post-stroke outcomes [22][23][24][25][26][27][28][29][30].…”

Section: Study Characteristicsmentioning

confidence: 99%

“…After evaluation, 19 articles were included in this systematic review [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] (Fig. 1), of which 10 investigated the value of serum sST-2 measurement in the prediction of the risk of stroke incidence [12][13][14][15][16][17][18][19][20][21], and the remaining 9 evaluated the value of serum sST-2 measurement in the prognosis of post-stroke outcomes [22][23][24][25][26][27][28][29][30]. A detailed description of the characteristics of these studies is provided in the respective sections.…”

Section: Study Characteristicsmentioning

confidence: 99%

Soluble Suppression of Tumorigenicity-2 as a Candidate Prognostic Marker for Stroke: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Background: Risk stratification of patients for incidence of stroke and its outcomes can aid in decision-making regarding treatment options and rehabilitative care. We systematically reviewed the literature to provide comprehensive evidence for the value of serum soluble suppression of tumorigenicity-2 (sST-2) in the prediction of stroke incidence and the evaluation of post-stroke outcomes.Methods: The Medline, Scopus, Web of Science, and Embase databases were searched until the end of August 2022 for studies investigating the value of serum sST-2 in the prediction of stroke incidence and post-stroke outcomes.Results: Nineteen articles were included. The articles reported conflicting results on the predictive value of sST-2 measurement in the incidence of stroke. Studies investigating the value of sST-2 measurement for the prognosis of post-stroke outcomes have reported positive associations between sST-2 levels and post-stroke mortality, composite adverse events, major disability, cerebral-cardiac syndrome, and cognitive impairment. Conclusions:Although some studies have reported a predictive value of serum sST-2 measurement in the incidence of stroke, a clear consensus has yet to be reached because of discrepancies in the results. As for the prognosis of post-stroke outcomes, sST-2 may be a predictor of mortality, composite adverse events, and major disability after stroke. Overall, more well-designed prospective cohort studies are needed to reach a more decisive conclusion on the value of sST-2 measurement for the prediction of stroke and its outcomes and to determine optimal cutoffs.

show abstract